Monday, July 13, 2026
A busy stretch heading into the back half of the year — and the week’s stories all trace the same fault line: the medtech growth engine is running hard, but scale is cutting both ways.
Two of the industry’s biggest names spent the week reshaping their portfolios in opposite directions — Roche muscling into sequencing, ResMed shedding software to fund its core — while the reimbursement map shifted underneath everyone with a sweeping CMS proposal and a landmark payer win for blood-based cancer screening. The counterweight was risk surfacing where the giants are most exposed: a Terumo aortic recall tied to three deaths, and Medtronic’s breach notification reaching nearly four million people. The throughline for operators: the same reach that drives growth now defines the downside, and quality systems, reimbursement strategy, and data governance are moving from back-office concerns to boardroom ones.
8 things to watch this week:
1. 🧬 Roche takes on Illumina with new NGS system
Roche launched Axelios 1, its long-teased sequencing platform built on new “sequencing by expansion” chemistry, priced at roughly $750K against Illumina’s NovaSeq X and targeting research labs first with a clinical path to follow. More than a decade after its failed hostile bid for Illumina, Roche is attacking the $7.3B market on price and speed rather than head-on — a reminder that in a mature category, the entry strategy matters as much as the technology.
Fierce Biotech
2. 💨 Resmed to sell software business MatrixCare for $490M to private equity firm
Resmed agreed to offload MatrixCare — a $220M-revenue post-acute EHR business it bought for $750M in 2018 — to Frazier Healthcare Partners, redirecting capital toward sleep, breathing, and connected home care. It’s a clean case study in portfolio discipline: a mature, slower-growing asset carved out so the core can compound faster, with proceeds funding buybacks rather than new bets.
MedTech Dive
3. 🧭 Where does your commercialization actually stand? Two minutes to find out.
Most medical device companies don't stall because the technology is wrong. They stall because the sequencing is — launching before the market's ready, scaling before the evidence lands, chasing the next milestone before the last one is proven. RŌG Health's Commercial Readiness Check is a short diagnostic that maps where your commercialization actually stands right now, across the gaps that quietly derail otherwise strong programs. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 🏛️ CMS targets 340B, site-neutral pay in 2027 outpatient rule
The CMS 2027 OPPS/ASC proposed rule, issued July 2, would deepen 340B drug payment cuts and push site-neutral payment into new outpatient categories — moves projected to pull billions from hospital outpatient revenue starting in 2027 and affecting roughly 3,500 hospitals and 6,400 ASCs. Device leaders should read the site-neutral expansion as a signal: as reimbursement flattens across care settings, the economics of where a procedure is performed — and who buys the device — are being rewritten. Comments close August 31.
Becker’s Hospital Review
5. ⚠️ Terumo initiates voluntary thoracic stent graft recall after 3 deaths
Terumo recalled roughly 7,000 RelayPro thoracic stent-grafts across 43 countries after four cases in which physicians couldn’t separate the delivery system from the deployed graft — three of which ended in patient deaths. Terumo hasn’t established direct causation but suspended shipments in March and has now expanded the action globally, a sharp reminder that delivery-system failures, not just the implant, sit squarely inside post-market risk.
MassDevice
6. 🔓 Major medical device manufacturer notifies nearly 4 million of breach
Medtronic began notifying nearly four million people that April’s ShinyHunters intrusion into its corporate IT systems exposed names, dates of birth, Social Security numbers, and health-related data — details that surfaced via a California AG notification filing. The company maintains device safety and operations were unaffected, but the notification scale underscores how patient-data liability now travels with any connected-device franchise, independent of clinical risk.
The Record
7. 🫀 Edwards Lifesciences crashes the LAA party — can the TAVR giant compete?
Edwards won 510(k) clearance for Ecliptis, its left atrial appendage exclusion clip, entering a crowded surgical LAA market against AtriCure’s AtriClip and Medtronic’s Penditure. Edwards is betting its structural-heart surgical relationships carry into a new therapeutic area — a textbook adjacency play whose success will hinge less on the device than on whether an established commercial channel actually transfers.
MD+DI
8. 🩸 Guardant’s Shield colon cancer blood test snags UnitedHealth coverage
UnitedHealth became the first major private U.S. insurer to reimburse Guardant’s Shield blood-based colorectal screening test, extending access to roughly 100 million people — a decision one analyst called a “watershed moment” for liquid biopsy. Notably, coverage arrived ahead of USPSTF inclusion, a reversal of the usual sequence that suggests commercial payers may increasingly move on category conviction rather than waiting for guideline consensus.
MedTech Dive
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.